In certain embodiments, any controlled release otic formulation or composition described herein increases the exposure of a therapeutic agent and increases the Area Under the Curve (AUC) in otic fluids (e.g., endolymph and/or perilymph) by about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% compared to a formulation or composition that is not a controlled release otic formulation or composition
Anytime from your account
Determination of the optimal dose of cagrilintide dose in chow-fed and HFD-fed WT mice In the first study, the acute response to three doses of cagrilintide were compared to the vehicle in WT 129S2 chow-fed mice
smegmatis mc 2 155 cobLMK strain, and after confirmation loss of pJV53H, this strain was electroporated with the pRES-FLP- Mtb plasmid to resolve the Kan R resistance cassette
Bevan-Thomas utilizes a customized, judgment-based approach to ensure each treatment plan fits the patients anatomy, goals, and prostate size
The Role of Kisspeptin and MKRN3 in the Diagnosis of Central Precocious Puberty in Girls
